The American Medical Association (AMA) will soon weigh in on a resolution to persuade the U.S. Food and Drug Administration to require drugmakers to include drug prices on direct-to-consumer (DTC) ads.
The AMA is preparing to vote on the resolution at an upcoming meeting, which could carry quite a bit of influence over industry regulators such as the FDA, according to a recent article from Toronto-based Xtalks.
“According to the AMA, in 1999, drugmakers spent $791 million on DTC advertising; seven years later, this number rose to a staggering $4.8 billion,” the article said. “DTC advertising of pharmaceuticals is only permitted in one other country besides the U.S: New Zealand."
In 2015, the AMA fought against DTC advertising and encouraged regulators to stop the practice in the U.S., according to the article. Despite cracking down on the drugmakers, TV, print and online ads for drugs and medical equipment remain dominate.
The AMA will also vote on several other resolutions during the meeting including drug companies explaining their price setting structure for new drugs and price increases on older drugs.